Type 2 diabetes: the role of the practice pharmacist
Muhammad Siddiqur Rahman highlights the integral role of practice-based pharmacists in managing type 2 diabetes
Co-morbidities in type 2 diabetes
Dr Kevin Fernando describes eight common co-morbidities in patients with type 2 diabetes and how the co-existing conditions should be managed
Type 2 diabetes: what are the benefits and risks of glucose-lowering agents?
Dr Kevin Fernando explains how SIGN 154 offers evidence-based guidance on glucose control therapies for people with type 2 diabetes
Top tips: type 2 diabetes
Dr Kevin Fernando provides top tips on diagnosing and managing type 2 diabetes and identifying people at high risk
An innovative diabetes service redesign in Wakefield
Dr Dinesh Nagi provides insight into an integrated model of care provided by primary care and specialist diabetes teams
Test and reflect
Our multiple-choice questions (MCQs) are designed to help you test your knowledge and reflect on your learning after reading an article.
Educational resources
Management of Type 2 Diabetes and Cardiovascular Disease
Information intended for healthcare professionals only. This supplement has been commissioned and funded by Boehringer Ingelheim Limited and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice. Please see the bottom of the page for full disclaimer.
Implementing the ADA and EASD 2018 consensus report: management of hyperglycaemia in type 2 diabetes
Information intended for healthcare professionals only. This checklist has been commissioned and funded by Boehringer Ingelheim Limited and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice. Please see the bottom of the page for full disclaimer.
Jardiance® (empagliflozin) film-coated tablets
This formulary decision guide was initiated, funded, and reviewed by Boehringer Ingelheim Limited and Lilly Diabetes Alliance. The format was developed by Guidelines in Practice.
Management of hyperglycaemia in type 2 diabetes, 2018: ADA/EASD consensus report
Watch this short animation, commissioned by Napp Pharmaceuticals Limited, to find out about the third joint consensus report on the management of hyperglycaemia in type 2 diabetes by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Semglee® ▼ (insulin glargine biosimilar)
This formulary decision guide was developed from content provided by Mylan Ltd in a format developed by Guidelines in Practice.
Related Guidelines summaries
-
Type 2 diabetes treatment pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN.
-
Type 2 diabetes: frailty in older people
Summary covers glycaemic targets for older people, priorities for improving high-quality diabetes care, and a useful frailty assessment pathway.
-
Pancreatic exocrine insufficiency guideline
This management algorithm was developed by a multidisciplinary expert panel: Hambling C et al with the support of a grant from Mylan Ltd.
-
SIGN type 2 diabetes guideline
This summary provides key recommendations on lifestyle management, treatment options, diabetic CVD, and CKD. Includes a useful treatment algorithm